Advaxis rises on promising early-stage data from cancer combo therapy

Ayala Pharmaceuticals

13/02/2020 14:04

** Drug developer's shares  ADXS.O  rise 10.1% to $1.20
premarket 
    ** Company says a combination of its experimental cancer
drug and Merck & Co's  MRK.N  Keytruda helped prostate cancer
patients survive for 16.4 months vs est 11 months with the
current standard of care  urn:newsml:reuters.com:*:nGNXW2Z3S
    ** Advaxis' drug ADXS-PSA was being tested in patients whose
cancer has spread and the disease is able to progress despite
castration
    ** The combination appeared safe and tolerable in this
heavily pre-treated population of patients - ADXS 
    ** Prostate cancer is one of the most common cancers in men
in the United States 
    ** ADXS shares plunged nearly 24% on July 23 after a $16 mln
capital raise  urn:newsml:reuters.com:*:nL2N24O0D9
    ** Stock has lost ~81% in the past 12 months

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780,
outside U.S. +91 806749 2709))